Literature DB >> 328208

Protein binding of cardiac glycosides in disease states.

L Storstein.   

Abstract

Digitoxin in 97% bound to serum albumin and digoxin only to the extent of 24%. Hypoalbuminaemia significantly changes the protein binding of digoxin in Kwashorkor serum and the binding of digitoxin in patients with chronic active hepatitis and the nephrotic syndrome. Sprue patiens with normal albumin values have normal binding of digitoxin. Preliminary data in patients with thyrotoxicosis and myxoedema show digitoxin binding within the normal range. The effect of uraemia per se on digitoxin binding is controversial as both normal and slightly decreased values have been reported. In uraemic patients on treatment with haemodialysis, heparin administration has been shown to be a powerful serum binding displacing agent for both digitoxin and digoxin, the mechanism probably being a heparin-induced release of free fatty acids. Patients with a significant decrease in serum protein binding of digitoxin or digoxin should be maintained on a total serum concentration lower than usually considered within the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 328208     DOI: 10.2165/00003088-197702030-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  38 in total

1.  Protein binding radioactive digitoxin.

Authors:  J L SPRATT; G T OKITA
Journal:  J Pharmacol Exp Ther       Date:  1958-10       Impact factor: 4.030

2.  [Determination of protein binding of different cardiac glycosides by means of Sephadex gel filtration].

Authors:  K Kuschinsky
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968

3.  [Plasma protein binding of cardiac glycosides in limited kidney function].

Authors:  A Hawlina; K H Rahn
Journal:  Verh Dtsch Ges Inn Med       Date:  1974

4.  Influence of free fatty acid concentration on drug binding to plasma albumin.

Authors:  A A Spector; E C Santos; J D Ashbrook; J E Fletcher
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

5.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

Review 6.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Plasma protein binding of digitoxin and digoxin in several mammalian species.

Authors:  J D Baggot; L E Davis
Journal:  Res Vet Sci       Date:  1973-07       Impact factor: 2.534

8.  Kinetics of elimination of drugs possessing high affinity for the plasma proteins.

Authors:  B K Martin
Journal:  Nature       Date:  1965-08-28       Impact factor: 49.962

9.  [Studies on the metabolism and distribution of cardiac glycosides. 3. Protein binding of digitoxin and its metabolites].

Authors:  S Uchida; Y Kinoshita; I Kusakari; M Fuse
Journal:  Yakugaku Zasshi       Date:  1965-07       Impact factor: 0.302

10.  The displacement of phenylbutazone-14C and warfarin-14C from human albumin by various drugs and fatty acids.

Authors:  H M Solomon; J J Schrogie; D Williams
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

View more
  12 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

3.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 4.  Drug interactions with digitalis glycosides.

Authors:  P F Binnion
Journal:  Drugs       Date:  1978-05       Impact factor: 9.546

Review 5.  Drug prescribing in renal failure.

Authors:  W M Bennett
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

Review 6.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

7.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 8.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

9.  Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients.

Authors:  F Fauvelle; O Lortholary; M Tod; L Guillevin; M Louchahi; A Léon; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Serum protein binding of propylthiouracil.

Authors:  J P Kampmann; J E Mølholm Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.